PASADENA, Calif.--(BUSINESS WIRE)--Sanguine Corporation (OTC Bulletin Board: SGNC) is pleased to announce that a meeting was held at the office in West Chester, Pennsylvania, with the Company’s GMP pharmaceutical manufacturer of PHER-O2 to discuss the product’s progress and stage of development. With the recent supply of PHER-O2 to a European medical research group for intravenous development and evaluation, Sanguine management elected to discuss the progress of PHER-O2’s master drug file, improved manufacturing and requirements necessary for long term supply of product. The details of the meeting were confidential, however both companies’ management were quite pleased with the progress and future of PHER-O2 as a transport medium for transplantable materials.
